Atomo Confirms Market-Sensitive Information Awareness Post Lumos CLIA Waiver Announcement

Material Information Recognized Post Waiver Announcement

Atomo Diagnostics Ltd (ASX:AT1) has provided a detailed response to ASX Compliance following an Aware Letter regarding its disclosure obligations tied to Lumos Diagnostics’ FDA CLIA waiver approval for the FebriDx test. The waiver, critical to Lumos' substantial US supply contract, directly impacts Atomo’s Pascal cassette manufacturing business.

Atomo firmly states it first became aware of disclosable, market-sensitive information only upon Lumos’ public announcement on 27 March 2026, prior to market open. This announcement confirmed the CLIA waiver approval with full details, enabling Atomo to properly assess commercial implications. Prior to this, Atomo had received only a vague preliminary email from Lumos on 25 March, which it judged insufficiently definite or verifiable to trigger disclosure obligations.

Trading Halt and Capital Raise Timing Explained

The company sought a trading halt on 26 March as a precautionary measure to prevent a false market, not because it held material information at that time. This halt coincided with an ASX price query about unusual trading activity. Atomo emphasised that no confidential or price-sensitive information was shared with brokers during initial discussions on the halt day.

Following the public waiver announcement, Atomo’s board resolved to proceed with a capital raise, mandating brokers and securing binding commitments over the weekend. The company released a comprehensive market announcement on 30 March, coinciding with the halt’s lifting and fully informing the market before trading resumed.

This sequence aligns with ASX Listing Rule 3.1 and Guidance Note 8 principles, which allow for a trading halt when an entity cannot immediately release complete and accurate information without risking a false market. Atomo’s approach contrasts with premature announcements that could mislead investors.

Distinguishing Preliminary Correspondence from Material Disclosure

Atomo’s response highlights the importance of distinguishing between preliminary, speculative information and confirmed, detailed disclosures. The company argued that the initial Lumos email was too vague to warrant disclosure and remained confidential. Even if considered price sensitive, it met Listing Rule 3.1A exceptions, including confidentiality and insufficient definiteness.

This stance is consistent with ASX guidance recognising that entities receiving information in instalments may delay disclosure until sufficient detail emerges. Atomo’s measured handling avoided potential market harm from releasing incomplete information.

Notably, this episode follows a recent surge in Atomo’s trading volume linked to Lumos’ FDA update, where the company also denied possessing undisclosed price-sensitive information, underscoring its cautious communication strategy.

Capital Raise Details and Market Impact

The capital raising announced on 30 March aimed to raise up to $4 million, comprising a $3 million placement and a $1 million share purchase plan. The placement shares were priced at 3.3 cents each, a roughly 10% discount to the recent VWAP, accompanied by free attaching options. Joint lead managers Alpine Capital and GBA Capital received fees and broker options, with Bay Financial as co-manager.

Despite the positive regulatory milestone, Atomo’s share price dipped slightly from 3.5 to 3.1 cents following the announcement, reflecting market digestion of the news and capital raising terms. Investors will be watching how Atomo leverages the CLIA waiver to scale Pascal cassette production and revenue growth.

Atomo’s exclusive supply role for Lumos’ FebriDx test, which recently secured the FDA CLIA waiver unlocking a significant US market expansion, remains a key growth driver. The company’s careful disclosure management during this period aligns with maintaining investor confidence amid evolving commercial developments, as documented in its recent Pascal cassette powers FebriDx approval.